Search results
Why Big Pharma Is Following Novartis' Lead In A $25 Billion Market
Investor's Business Daily· 3 hours agoNovartis blazed a trail for treating cancer with targeted radiopharmaceuticals, a treatment that...
H.C. Wainwright lowers Arvinas shares target amid Novartis licensing deal for ARV-766 By...
Investing.com· 2 weeks agoArvinas revealed on Thursday that it had entered into a license agreement with Novartis for ARV-766,...
Novartis (NYSE:NVS) Price Target Increased to $116.00 by Analysts at BMO Capital Markets
ETF DAILY NEWS· 9 hours agoNovartis (NYSE:NVS – Free Report) had its price target raised by BMO Capital Markets from $114.00 to $116.00 in a report issued on Wednesday, Benzinga reports ...
Novartis bags paediatric FDA label expansion for Lutathera
Pharmaceutical Technology via Yahoo Finance· 1 day agoFDA first approved Lutathera as a combination therapy with a long-acting octreotide for the same...
20 Countries with the Highest Rates of Stomach Cancer in the World
Insider Monkey via Yahoo Finance· 3 hours agoIn this article, we will be taking a look at the 20 countries with the highest rates of stomach...
Novartis (NVS) Q1 Earnings, Sales Beat, Guidance Raised
Zacks via Yahoo Finance· 2 days agoThe transaction will close in the second quarter of 2024. Novartis also entered into an exclusive...
Novartis AG (NYSE:NVS) Expected to Post Q3 2025 Earnings of $1.98 Per Share
ETF DAILY NEWS· 1 day agoNovartis AG (NYSE:NVS – Free Report) – Analysts at Zacks Research cut their Q3 2025 earnings per share estimates for shares of Novartis in a note issued ...
Novartis radioligand therapy Lutathera® FDA approved as first medicine specifically for pediatric...
WTNH-TV New Haven· 2 days agoNovartis today announced that the U.S. Food and Drug Administration (FDA) approved Lutathera®...
Novartis (NVS) Inks Deal for ARVN's Prostate Cancer Candidate
Zacks via Yahoo Finance· 2 weeks agoNovartis (NVS) enters into a license deal with Arvinas, Inc. (ARVN) for the worldwide development ...
Novartis Kesimpta® six-year efficacy data show substantial benefits in recently diagnosed...
WDTN-TV 2 Dayton· 1 week ago...outcomes were demonstrated in a separate analysis of continuous Kesimpta treatment for up to six years in the overall ALITHIOS study population2 Switch from teriflunomide to Kesimpta resulted in significant improvements across several efficacy outcomes such as annualized relapse rate and MRI...